Non-coding RNAs and glioma: Focus on cancer stem cells.

in Molecular therapy oncolytics by Ali Rajabi, Mehrdad Kayedi, Shiva Rahimi, Fatemeh Dashti, Seyed Mohammad Ali Mirazimi, Mina Homayoonfal, Seyed Mohammad Amin Mahdian, Michael R Hamblin, Omid Reza Tamtaji, Ali Afrasiabi, Ameneh Jafari, Hamed Mirzaei

TLDR

  • The study is about how non-coding RNAs (ncRNAs) work in the development and progression of a type of brain tumor called gliomas. It also talks about how these RNAs could be used as markers and targets for treating gliomas in the future.

Abstract

Glioblastoma and gliomas can have a wide range of histopathologic subtypes. These heterogeneous histologic phenotypes originate from tumor cells with the distinct functions of tumorigenesis and self-renewal, called glioma stem cells (GSCs). GSCs are characterized based on multi-layered epigenetic mechanisms, which control the expression of many genes. This epigenetic regulatory mechanism is often based on functional non-coding RNAs (ncRNAs). ncRNAs have become increasingly important in the pathogenesis of human cancer and work as oncogenes or tumor suppressors to regulate carcinogenesis and progression. These RNAs by being involved in chromatin remodeling and modification, transcriptional regulation, and alternative splicing of pre-mRNA, as well as mRNA stability and protein translation, play a key role in tumor development and progression. Numerous studies have been performed to try to understand the dysregulation pattern of these ncRNAs in tumors and cancer stem cells (CSCs), which show robust differentiation and self-regeneration capacity. This review provides recent findings on the role of ncRNAs in glioma development and progression, particularly their effects on CSCs, thus accelerating the clinical implementation of ncRNAs as promising tumor biomarkers and therapeutic targets.

Overview

  • The study focuses on the role of non-coding RNAs (ncRNAs) in the development and progression of gliomas, specifically their effects on cancer stem cells (CSCs).
  • The methodology used for the experiment includes a review of recent studies on the topic, with a focus on understanding the dysregulation pattern of ncRNAs in tumors and CSCs.

Comparative Analysis & Findings

  • The study compares the outcomes observed under different experimental conditions or interventions related to ncRNAs in gliomas and CSCs. It identifies significant differences or similarities in the results between these conditions, particularly in terms of their effects on tumor development and progression.

Implications and Future Directions

  • The study's findings highlight the significance of ncRNAs in glioma development and progression, particularly their effects on CSCs. They suggest that ncRNAs could be used as promising tumor biomarkers and therapeutic targets in the clinical implementation of ncRNAs in cancer treatment. Future research directions could focus on further understanding the mechanisms underlying ncRNA dysregulation in gliomas and CSCs, as well as developing novel ncRNA-based therapies for glioma treatment.